AI Article Synopsis
- A case report details a 62-year-old woman with multiple myeloma who developed eye issues after starting teclistamab, a new treatment for her condition.
- She experienced right eye pain and reduced vision, leading to the diagnosis of sclerouveitis with hypopyon shortly after beginning the medication.
- Treatment involved antibiotics and steroids; her condition improved, suggesting that teclistamab might be related to her eye complications based on a probable adverse drug reaction assessment.
Article Abstract
Purpose: To report a case of presumed teclistamab-associated sclerouveitis with hypopyon.
Methods: Case report.
Results: A 62-year-old woman with relapsed refractory multiple myeloma presented with right eye pain and decreased vision 1 week after starting teclistamab and was found to have sclerouveitis with hypopyon. She received intravitreal vancomycin and ceftazidime because of the concern for infectious endophthalmitis, but cultures were negative. Systemic workup for infectious and inflammatory etiologies was unremarkable. Her signs and symptoms improved with topical steroids and a 1-week pause in teclistamab. This case constituted a Naranjo Adverse Drug Reaction Probability Scale score of 5, representing a "probable" association.
Conclusion: Teclistamab, a novel bispecific antibody recently approved for the treatment of relapsed or refractory multiple myeloma, may be associated with sclerouveitis with hypopyon.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ICB.0000000000001449 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!